$23.14
+0.22
(+0.96%)▲
1.47%
Downside
Day's Volatility :2.36%
Upside
0.9%
25.5%
Downside
52 Weeks Volatility :31.15%
Upside
7.59%
Period | Avanos Medical, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 26.63% | 6.5% | 0.0% |
6 Months | 19.62% | 7.1% | 0.0% |
1 Year | -7.47% | 9.8% | 0.0% |
3 Years | -35.56% | 14.2% | -20.2% |
Market Capitalization | 1.0B |
Book Value | $26.58 |
Earnings Per Share (EPS) | -0.03 |
Wall Street Target Price | 23.5 |
Profit Margin | -9.15% |
Operating Margin TTM | 4.51% |
Return On Assets TTM | 2.18% |
Return On Equity TTM | -0.13% |
Revenue TTM | 680.1M |
Revenue Per Share TTM | 14.63 |
Quarterly Revenue Growth YOY | 4.3% |
Gross Profit TTM | 450.0M |
EBITDA | 104.7M |
Diluted Eps TTM | -0.03 |
Quarterly Earnings Growth YOY | -0.37 |
EPS Estimate Current Year | 1.37 |
EPS Estimate Next Year | 1.81 |
EPS Estimate Current Quarter | 0.21 |
EPS Estimate Next Quarter | 0.28 |
What analysts predicted
Upside of 1.56%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 652.3M | ↑ 6.65% |
Net Income | 57.5M | ↓ 27.49% |
Net Profit Margin | 8.81% | ↓ 4.16% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 697.6M | ↑ 6.94% |
Net Income | -45.9M | ↓ 179.83% |
Net Profit Margin | -6.58% | ↓ 15.39% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 714.8M | ↑ 2.47% |
Net Income | -27.2M | ↓ 40.74% |
Net Profit Margin | -3.81% | ↑ 2.77% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 744.6M | ↑ 4.17% |
Net Income | 6.3M | ↓ 123.16% |
Net Profit Margin | 0.85% | ↑ 4.66% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 820.0M | ↑ 10.13% |
Net Income | 50.5M | ↑ 701.59% |
Net Profit Margin | 6.16% | ↑ 5.31% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 673.3M | ↓ 17.89% |
Net Income | -61.8M | ↓ 222.38% |
Net Profit Margin | -9.18% | ↓ 15.34% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 217.5M | ↑ 7.62% |
Net Income | 16.9M | ↑ 7.64% |
Net Profit Margin | 7.77% | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 191.7M | ↓ 11.86% |
Net Income | -500.0K | ↓ 102.96% |
Net Profit Margin | -0.26% | ↓ 8.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 169.4M | ↓ 11.63% |
Net Income | -68.1M | ↑ 13520.0% |
Net Profit Margin | -40.2% | ↓ 39.94% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 171.3M | ↑ 1.12% |
Net Income | -3.7M | ↓ 94.57% |
Net Profit Margin | -2.16% | ↑ 38.04% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 173.3M | ↑ 1.17% |
Net Income | 10.5M | ↓ 383.78% |
Net Profit Margin | 6.06% | ↑ 8.22% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 166.1M | ↓ 4.15% |
Net Income | -900.0K | ↓ 108.57% |
Net Profit Margin | -0.54% | ↓ 6.6% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↓ 16.51% |
Total Liabilities | 536.2M | ↓ 45.31% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↓ 1.84% |
Total Liabilities | 534.4M | ↓ 0.34% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↓ 7.05% |
Total Liabilities | 416.3M | ↓ 22.1% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↓ 4.67% |
Total Liabilities | 330.7M | ↓ 20.56% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 12.06% |
Total Liabilities | 495.7M | ↑ 49.89% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↓ 5.29% |
Total Liabilities | 456.1M | ↓ 7.99% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↑ 0.66% |
Total Liabilities | 495.7M | ↓ 3.13% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 2.91% |
Total Liabilities | 436.2M | ↓ 12.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 3.93% |
Total Liabilities | 431.9M | ↓ 0.99% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↑ 3.49% |
Total Liabilities | 502.8M | ↑ 16.42% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 1.88% |
Total Liabilities | 456.1M | ↓ 9.29% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 1.84% |
Total Liabilities | 433.4M | ↓ 4.98% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -145.6M | ↓ 200.97% |
Investing Cash Flow | 639.5M | ↓ 1583.76% |
Financing Cash Flow | -324.4M | ↓ 14845.45% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -74.5M | ↓ 48.83% |
Investing Cash Flow | -108.1M | ↓ 116.9% |
Financing Cash Flow | 1.5M | ↓ 100.46% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.5M | ↓ 96.64% |
Investing Cash Flow | -24.2M | ↓ 77.61% |
Financing Cash Flow | -70.0M | ↓ 4766.67% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 87.3M | ↓ 3592.0% |
Investing Cash Flow | -21.0M | ↓ 13.22% |
Financing Cash Flow | -55.3M | ↓ 21.0% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 90.9M | ↑ 4.12% |
Investing Cash Flow | -135.4M | ↑ 544.76% |
Financing Cash Flow | 56.7M | ↓ 202.53% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 33.7M | ↑ 18.66% |
Investing Cash Flow | -4.9M | ↑ 4.26% |
Financing Cash Flow | -21.9M | ↑ 114.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.8M | ↓ 120.18% |
Investing Cash Flow | -4.0M | ↓ 18.37% |
Financing Cash Flow | -22.1M | ↑ 0.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.6M | ↓ 61.76% |
Investing Cash Flow | -6.5M | ↑ 62.5% |
Financing Cash Flow | -4.1M | ↓ 81.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 29.1M | ↓ 1219.23% |
Investing Cash Flow | -48.9M | ↑ 652.31% |
Financing Cash Flow | 46.7M | ↓ 1239.02% |
Sell
Neutral
Buy
Avanos Medical, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Avanos Medical, Inc. | 19.5% | 19.62% | -7.47% | -35.56% | -45.4% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Avanos Medical, Inc. | 52.7 | NA | NA | 1.37 | 0.0 | 0.02 | NA | 26.58 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Avanos Medical, Inc. | Buy | $1.0B | -45.4% | 52.7 | -9.15% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Avanos Medical, Inc.
Revenue is down for the last 2 quarters, 173.3M → 166.1M (in $), with an average decrease of 4.2% per quarter
Netprofit is down for the last 2 quarters, 10.5M → -900.0K (in $), with an average decrease of 108.6% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 49.2%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 104.5%
BlackRock Inc
Vanguard Group Inc
RGM Capital LLC
Dimensional Fund Advisors, Inc.
Westwood Holdings Group Inc
State Street Corporation
avanos is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter.headquartered in alpharetta, georgia, avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery.avanos develops, manufactures and markets its recognized brands in more than 90 countries.
Organization | Avanos Medical, Inc. |
Employees | 3771 |
CEO | Mr. Joseph F. Woody |
Industry | Health Technology |
A Spac I Acquisition Corp
$23.14
+0.96%
Keyarch Acquisition Corp
$23.14
+0.96%
Connexa Sports Technologies Inc
$23.14
+0.96%
Us Value Etf
$23.14
+0.96%
First Wave Biopharma Inc
$23.14
+0.96%
Global X Msci Next Emerging
$23.14
+0.96%
Fat Projects Acquisition Corp
$23.14
+0.96%
Capital Link Global Fintech
$23.14
+0.96%
Applied Uv Inc
$23.14
+0.96%